Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1Hypertension 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Angiotensin-Converting Enzyme Inhibitors × Dermatologic × Clear all
NCT04334824 2024-09-19

Hydrochlorothiazide and Risk of Skin Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
2,953,748 enrolled
Dermatologic

Hypertension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡